EWING, N.J.--(BUSINESS WIRE)--Antares Pharma, Inc. (NASDAQ: ATRS) today announced positive results from a multi-center phase 2 clinical study evaluating the pharmacokinetic profile of testosterone ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback